The CA-62 biomarker is a unique cancer marker that is indicative of the presence of various epithelial carcinomas. The maximum level of expressed CA-62 biomarker is observed at early stages of cancer, when tumor cells are poorly differentiated. UCT’s CA-62 Biomarker Cancer Test can detect cancer at the earliest stages of its development with a high level of sensitivity (>90%) and specificity (95%).
Besides early cancer detection, the innovative UCT CA-62 Biomarker Cancer Test can also be used to monitor patients with disseminated cancers , to evaluate the cancer treatment effectiveness and to detect early cancer recurrence in the patients. These applications were clearly demonstrated by the results of a recent blind clinical study. Data analysis obtained from this pilot study concluded that the expression of the CA-62 biomarker correlates well with tumor growth and treatment responses. The UCT CA-62 Biomarker Cancer Test can be used as a tumor growth inhibition indicator as applied to the assessment of ongoing patient treatment procedures and for the timely detection of chemotherapy resistance. In the future, this may be successfully used in a clinical practice to monitor malignant neoplasms of the gastrointestinal tract, ovaries, lungs, large intestine, and rectum.
The CA-62 Biomarker Cancer Test has been used to study a wide range of carcinomas including breast cancer, prostate cancer, stomach cancer, colorectal cancer, lung cancer, liver cancer, cervical cancer, ovarian cancer, melanoma, intestinal cancer, myeloma, esophageal cancer, and glioblastoma , representing the majority of epithelial cancer types. All of these studied cancers have demonstrated a high level of CA-62 biomarker expression, confirming that it is specific to epithelial carcinomas.
The high level of positive predicting value (PPV) seen with the UCT Biomarker Cancer Test approaches the level of the pathomorphological accuracy. The patent for the technology and more than five articles outlining the results of these studies have been published in peer-reviewed scientific journals.
Measures the proportion of actual positives that are correctly identified
Measures the proportion of actual negatives that are correctly identified
The percentage of results that indicate a positive but are actually absent of cancer
Results demonstrated in 15 studies of stage I-IV cancers
Poster Washington 19-21 August 2024, 16th Annual Next Generation DX Summit
ASCO® 2024 Insights: "CA-62 - A New Biomarker for the Detection of Early Stage RCC"
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4526
A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1)and early-stage NSC lung cancer detection.
Sessions begins together with UCM Technologies on Jun 3, 2023 at 8:00AM
Hall A1 12000